NASDAQ:IMAB I-Mab (IMAB) Stock Price, News & Analysis → This could mean the end of the U.S dollar… (From Colonial Metals) (Ad) Free IMAB Stock Alerts $1.76 +0.00 (+0.08%) (As of 10:03 AM ET) Add Compare Share Share Today's Range$1.75▼$1.7850-Day Range$1.75▼$1.9052-Week Range$1.16▼$3.38Volume37,161 shsAverage Volume394,359 shsMarket Capitalization$142.46 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get I-Mab alerts: Email Address I-Mab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside595.5% Upside$12.25 Price TargetShort InterestHealthy1.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.15) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 starsMedical Sector429th out of 920 stocksPharmaceutical Preparations Industry194th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingI-Mab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageI-Mab has only been the subject of 3 research reports in the past 90 days.Read more about I-Mab's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.43% of the outstanding shares of I-Mab have been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in I-Mab has recently decreased by 10.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldI-Mab does not currently pay a dividend.Dividend GrowthI-Mab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMAB. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for I-Mab this week, compared to 1 article on an average week.Search InterestOnly 17 people have searched for IMAB on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added I-Mab to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, I-Mab insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.38% of the stock of I-Mab is held by institutions.Read more about I-Mab's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for I-Mab are expected to grow in the coming year, from ($2.15) to ($1.72) per share.Price to Book Value per Share RatioI-Mab has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMust-See: Elon’s New Invention is Absolutely InsaneSee what Elon Musk's new invention does and how it works… You will NOT believe it.Click here to see it About I-Mab Stock (NASDAQ:IMAB)I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Read More IMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMAB Stock News HeadlinesMay 22 at 7:00 AM | prnewswire.comI-Mab to Participate at the Jefferies Global Healthcare ConferenceApril 30, 2024 | prnewswire.comI-MAB Filed 2023 Annual Report on Form 20-FApril 16, 2024 | msn.comOmega Therapeutics CFO Joshua Reed to departApril 12, 2024 | markets.businessinsider.comI-MAB Buy Rating Justified by Strong Leadership and Promising PipelineApril 5, 2024 | prnewswire.comI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | investing.comI-Mab completes divestiture of its Shanghai unit for $80 millionApril 2, 2024 | uk.finance.yahoo.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaApril 2, 2024 | prnewswire.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaMarch 18, 2024 | finance.yahoo.comI-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2024 | finance.yahoo.comI-Mab Reports Full Year 2023 Financial Results and Business UpdateFebruary 22, 2024 | benzinga.comI-MAB Stock (NASDAQ:IMAB), Short Interest ReportFebruary 18, 2024 | seekingalpha.comI-Mab: Trading Below Net Cash With Multiple Upside OptionsFebruary 7, 2024 | marketwatch.comI-Mab to Divest Chinese Unit for Up to $80MFebruary 7, 2024 | msn.comI-Mab to divest Chinese assets amid rising geopolitical tensionsFebruary 7, 2024 | finance.yahoo.comI-Mab Signs Agreement to Divest its Assets and Business Operations in ChinaJanuary 11, 2024 | msn.comAsian Equities Traded in the US as American Depositary Receipts Advance in Thursday TradingDecember 31, 2023 | uk.finance.yahoo.comI-Mab (IMAB) interactive stock chart – Yahoo FinanceDecember 28, 2023 | benzinga.comI-MAB Stock (NASDAQ:IMAB) Dividends: History, Yield and DatesNovember 19, 2023 | finance.yahoo.comIndividual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%November 6, 2023 | finance.yahoo.comI-Mab Announces Participation at Jefferies and Piper Conferences in NovemberNovember 2, 2023 | msn.comI-Mab gains FDA breakthrough tag for kidney disease therapyNovember 2, 2023 | markets.businessinsider.comI-Mab:Felzartamab Granted Breakthrough Therapy Designation By FDA For Primary Membranous NephropathyNovember 2, 2023 | finance.yahoo.comFelzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)November 1, 2023 | finance.yahoo.comI-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023October 16, 2023 | finance.yahoo.comI-Mab Announces Phase 1 Data of Givastomig at ESMO 2023See More Headlines Receive IMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMAB CUSIPN/A CIK1778016 Webwww.i-mabbiopharma.com Phone86-21-6057-8000FaxN/AEmployees228Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+595.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.67 Quick Ratio5.67 Sales & Book Value Annual Sales$3.89 million Price / Sales36.62 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book0.60Miscellaneous Outstanding Shares80,880,000Free Float63,008,000Market Cap$142.46 million OptionableOptionable Beta1.10 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Raj Kannan (Age 60)CEO & Director Dr. Jerry WangCo-Founder & Chief Scientific OfficerMr. Skelton JosephChief Financial OfficerMr. Tianyi ZhangVice President of Investor RelationsDr. Fernando J. Salle´s Ph.D.Senior VP and Head of U.S. & EU Business DevelopmentClaire XuHead of US siteMs. Min Yin (Age 54)Senior Vice President of Operations Dr. Louie Naumovski M.D.Ph.D., Interim Chief Medical OfficerMr. Tyler EhlerSenior Director of Investor RelationsMore ExecutivesKey CompetitorsRenovaroNASDAQ:RENBRepare TherapeuticsNASDAQ:RPTXCytomX TherapeuticsNASDAQ:CTMXCybinNYSE:CYBNscPharmaceuticalsNASDAQ:SCPHView All CompetitorsInstitutional OwnershipGSA Capital Partners LLPSold 105,498 shares on 5/3/2024Ownership: 0.536%Nomura Holdings Inc.Sold 374,085 shares on 3/27/2024Ownership: 0.029%View All Institutional Transactions IMAB Stock Analysis - Frequently Asked Questions Should I buy or sell I-Mab stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMAB shares. View IMAB analyst ratings or view top-rated stocks. What is I-Mab's stock price target for 2024? 4 brokerages have issued 12-month target prices for I-Mab's stock. Their IMAB share price targets range from $6.00 to $25.00. On average, they anticipate the company's stock price to reach $12.25 in the next year. This suggests a possible upside of 595.5% from the stock's current price. View analysts price targets for IMAB or view top-rated stocks among Wall Street analysts. How have IMAB shares performed in 2024? I-Mab's stock was trading at $1.90 at the start of the year. Since then, IMAB stock has decreased by 7.3% and is now trading at $1.7612. View the best growth stocks for 2024 here. What other stocks do shareholders of I-Mab own? Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ). When did I-Mab IPO? I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers. Who are I-Mab's major shareholders? I-Mab's stock is owned by a number of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.54%). How do I buy shares of I-Mab? Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMAB) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersBitcoin’s Biggest Year YetParadigm PressDividend-like income from non-dividend stocksUnstoppable ProsperityWrite this ticker symbol down…StocksToTradeThis could mean the end of the U.S dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersGold Set to EXPLODE!Gold Safe Exchange[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.